Your browser doesn't support javascript.
loading
COVID-19 and mental health treatment in primary care: Impacts of a global pandemic on a psychopharmacological collaborative care management program.
Zuschlag, Zachary D; Lord, Benjamin; Smith, Teagan; Lengerich, Alexander; Leonard, Kaitlin; Guereca, Yvette; Kumar, Ambuj; Milsom, Vanessa A.
Afiliación
  • Zuschlag ZD; Mental Health and Behavioral Sciences Service, James A. Haley Veterans' Hospital, Tampa, FL, USA.
  • Lord B; Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA.
  • Smith T; Mental Health and Behavioral Sciences Service, James A. Haley Veterans' Hospital, Tampa, FL, USA.
  • Lengerich A; Research Methodology and Biostatistics Core, University of South Florida, Tampa, FL, USA.
  • Leonard K; Department of Psychiatry and Behavioral Health, VA Central Ohio Health Care, Grove City, OH, USA.
  • Guereca Y; VA ORD Strategic Initiative for Research and EHR Synergy (OSIRIS), Edward Hines, Jr. VA Hospital, Chicago, IL, USA.
  • Kumar A; Mental Health and Behavioral Sciences Service, James A. Haley Veterans' Hospital, Tampa, FL, USA.
  • Milsom VA; Research Methodology and Biostatistics Core, University of South Florida, Tampa, FL, USA.
Int J Psychiatry Med ; : 912174241264592, 2024 Jun 22.
Article en En | MEDLINE | ID: mdl-38907723
ABSTRACT

OBJECTIVE:

The COVID-19 pandemic has had a profound impact on individuals with mental health (MH) disorders and on the delivery of MH services. Studies examining treatment models which did not require substantial changes to the delivery of services during pandemic restrictions, such as collaborative care management (CoCM) programs are minimal. Therefore, a longitudinal retrospective cohort analysis was conducted to examine the impacts of the COVID-19 pandemic on a psychopharmacological CoCM program.

METHOD:

Data was collected on all U.S. Veterans enrolled in a CoCM program at a large VA during the first 10 months of the COVID-19 pandemic and compared to a one-year prior date matched control group. Treatment in the program pre-COVID vs. treatment during the pandemic was compared in relation to baseline symptomatology, improvements in MH symptoms, and program adherence.

RESULTS:

462 Veterans were referred during the control dates, compared to 351 during the pandemic. Veterans enrolled during the first four months of each study arm, done to allow for a minimum of 6 months of follow up data, had no differences in baseline symptoms of depression or anxiety. Veterans receiving care during the pandemic had higher rates of program completion than pre-pandemic controls. COVID-era Veterans had higher rates of depression response than controls, and no differences were observed in depression remission, anxiety response, or anxiety remission.

CONCLUSIONS:

Psychopharmacological CoCM treatment models can successfully manage depression and anxiety with no observed decrease in the effectiveness of this intervention even during periods of unprecedented disruptions to the delivery of MH services.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Psychiatry Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Psychiatry Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos